JP2012525385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525385A5 JP2012525385A5 JP2012508485A JP2012508485A JP2012525385A5 JP 2012525385 A5 JP2012525385 A5 JP 2012525385A5 JP 2012508485 A JP2012508485 A JP 2012508485A JP 2012508485 A JP2012508485 A JP 2012508485A JP 2012525385 A5 JP2012525385 A5 JP 2012525385A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- disease
- pharmaceutical formulation
- administered
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 22
- 229960004419 dimethyl fumarate Drugs 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 13
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 13
- 229940005650 monomethyl fumarate Drugs 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 11
- -1 microtablet Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 2
- 206010016825 Flushing Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 33
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 15
- 230000004770 neurodegeneration Effects 0.000 description 15
- 230000003959 neuroinflammation Effects 0.000 description 15
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 12
- 201000011240 Frontotemporal dementia Diseases 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 206010018341 Gliosis Diseases 0.000 description 7
- 208000037875 astrocytosis Diseases 0.000 description 7
- 230000007341 astrogliosis Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 6
- 101150102665 CCL20 gene Proteins 0.000 description 6
- 101150093802 CXCL1 gene Proteins 0.000 description 6
- 101150077124 CXCL10 gene Proteins 0.000 description 6
- 206010008025 Cerebellar ataxia Diseases 0.000 description 6
- 101150031350 Cxcl2 gene Proteins 0.000 description 6
- 101150102927 Cxcl3 gene Proteins 0.000 description 6
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 6
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 6
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 6
- 208000021642 Muscular disease Diseases 0.000 description 6
- 201000009623 Myopathy Diseases 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 6
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 6
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 5
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 5
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 101100369986 Mus musculus Tnfaip2 gene Proteins 0.000 description 4
- 101150091206 Nfkbia gene Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 206010030875 ophthalmoplegia Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 206010065040 AIDS dementia complex Diseases 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 3
- 208000011403 Alexander disease Diseases 0.000 description 3
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 102000014461 Ataxins Human genes 0.000 description 3
- 108010078286 Ataxins Proteins 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 3
- 208000022526 Canavan disease Diseases 0.000 description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 208000024412 Friedreich ataxia Diseases 0.000 description 3
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 3
- 101150005894 GCLC gene Proteins 0.000 description 3
- 101150096192 GGT1 gene Proteins 0.000 description 3
- 101150037699 GSTA2 gene Proteins 0.000 description 3
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 208000027747 Kennedy disease Diseases 0.000 description 3
- 208000028226 Krabbe disease Diseases 0.000 description 3
- 208000009829 Lewy Body Disease Diseases 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 3
- 208000001089 Multiple system atrophy Diseases 0.000 description 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 3
- 206010052057 Neuroborreliosis Diseases 0.000 description 3
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 3
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 3
- 208000031845 Pernicious anaemia Diseases 0.000 description 3
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 3
- 102000029797 Prion Human genes 0.000 description 3
- 108091000054 Prion Proteins 0.000 description 3
- 208000024777 Prion disease Diseases 0.000 description 3
- 208000005587 Refsum Disease Diseases 0.000 description 3
- 208000021811 Sandhoff disease Diseases 0.000 description 3
- 208000021235 Schilder disease Diseases 0.000 description 3
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 3
- 101150101311 Sqstm1 gene Proteins 0.000 description 3
- 101150074234 TXNRD1 gene Proteins 0.000 description 3
- 206010043189 Telangiectasia Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 3
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 3
- 208000030597 adult Refsum disease Diseases 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 206010008129 cerebral palsy Diseases 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 3
- 201000006061 fatal familial insomnia Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 101150096281 gsta3 gene Proteins 0.000 description 3
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 3
- 208000006443 lactic acidosis Diseases 0.000 description 3
- 201000010901 lateral sclerosis Diseases 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 201000003631 narcolepsy Diseases 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 101150075804 nqo1 gene Proteins 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 208000009056 telangiectasis Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010016717 Fistula Diseases 0.000 description 2
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000024571 Pick disease Diseases 0.000 description 2
- 241000206607 Porphyra umbilicalis Species 0.000 description 2
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000008741 proinflammatory signaling process Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17379709P | 2009-04-29 | 2009-04-29 | |
| US61/173,797 | 2009-04-29 | ||
| US17527009P | 2009-05-04 | 2009-05-04 | |
| US61/175,270 | 2009-05-04 | ||
| PCT/US2010/001282 WO2010126605A1 (en) | 2009-04-29 | 2010-04-29 | Treatment of neurodegeneration and neuroinflammation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014239565A Division JP2015044855A (ja) | 2009-04-29 | 2014-11-27 | 神経変性および神経炎症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525385A JP2012525385A (ja) | 2012-10-22 |
| JP2012525385A5 true JP2012525385A5 (cg-RX-API-DMAC7.html) | 2013-10-10 |
Family
ID=43032484
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012508485A Withdrawn JP2012525385A (ja) | 2009-04-29 | 2010-04-29 | 神経変性および神経炎症の治療 |
| JP2014239565A Pending JP2015044855A (ja) | 2009-04-29 | 2014-11-27 | 神経変性および神経炎症の治療 |
| JP2016090250A Pending JP2016175926A (ja) | 2009-04-29 | 2016-04-28 | 神経変性および神経炎症の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014239565A Pending JP2015044855A (ja) | 2009-04-29 | 2014-11-27 | 神経変性および神経炎症の治療 |
| JP2016090250A Pending JP2016175926A (ja) | 2009-04-29 | 2016-04-28 | 神経変性および神経炎症の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20120165404A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3318249A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2012525385A (cg-RX-API-DMAC7.html) |
| CN (2) | CN102427727A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010242064A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2760133A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1255133A1 (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ595941A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010126605A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DK1663197T3 (da) | 2003-09-09 | 2008-01-07 | Fumapharm Ag | Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma |
| SI1799196T1 (sl) | 2004-10-08 | 2016-10-28 | Forward Pharma A/S | Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline |
| HUE032251T2 (en) * | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| EP2653873B8 (en) | 2007-02-08 | 2022-08-24 | Biogen MA Inc. | Compositions and uses for treating Multiple Sclerosis |
| MX2011001341A (es) | 2008-08-19 | 2011-03-29 | Xenoport Inc | Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso. |
| EP2564839B1 (en) | 2009-01-09 | 2016-05-11 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| JPWO2010098429A1 (ja) | 2009-02-27 | 2012-09-06 | 国立大学法人大阪大学 | 免疫アジュバント組成物、及びその利用 |
| EP3318249A1 (en) * | 2009-04-29 | 2018-05-09 | Biogen MA Inc. | Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis |
| US20140142095A1 (en) * | 2011-04-28 | 2014-05-22 | Serket Pharma, Llc | Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| MX2013013781A (es) * | 2011-05-26 | 2014-01-08 | Biogen Idec Inc | Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina. |
| PE20141639A1 (es) | 2011-06-08 | 2014-11-08 | Biogen Idec Inc | Proceso para preparar fumarato de dimetilo de alta pureza y cristalino |
| EP2791181A4 (en) * | 2011-12-16 | 2015-08-05 | Biogen Ma Inc | SILICONE-CONTAINING FUMIC ACID ESTERS |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CA2862885C (en) * | 2012-02-07 | 2020-06-02 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| JP2013220090A (ja) * | 2012-04-19 | 2013-10-28 | Tohoku Univ | 眼疾患治療に使用する薬剤スクリーニング方法 |
| EP2887934A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| US9597292B2 (en) | 2012-08-22 | 2017-03-21 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US20140171504A1 (en) | 2012-12-14 | 2014-06-19 | Georgia Regents Research Institute, Inc. | Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters |
| AR094277A1 (es) * | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| CN103173544B (zh) * | 2013-03-05 | 2015-01-28 | 浙江大学 | Leber病之线粒体T3866C检测试剂盒及应用 |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| MX386935B (es) | 2013-03-14 | 2025-03-04 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. |
| US10179118B2 (en) * | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| JP2016534133A (ja) | 2013-09-06 | 2016-11-04 | ゼノポート,インコーポレイティド | (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用 |
| CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
| MY179355A (en) * | 2013-12-12 | 2020-11-05 | Almirall Sa | Pharmaceutical compositions comprising dimethyl fumarate |
| JP6337135B2 (ja) | 2014-02-24 | 2018-06-06 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用 |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| CA2939990C (en) | 2014-02-28 | 2018-07-10 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40990A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulations de matrice pharmaceutique comprenant du fumarate de diméthyle |
| IL252962B (en) | 2015-02-08 | 2022-07-01 | Alkermes Pharma Ireland Ltd | Monomethylfumarate prodrug compositions |
| MA41785A (fr) | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| WO2017056107A1 (en) * | 2015-09-28 | 2017-04-06 | Natco Pharma Ltd | Pharmaceutical compositions of dimethyl fumarate |
| GR1009149B (el) * | 2016-10-25 | 2017-10-31 | Φαρματεν Αβεε | Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων |
| JP7084689B2 (ja) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | 脳組織の異常を伴う非ヒト動物の作製方法およびその利用 |
| CN110636838A (zh) | 2017-06-23 | 2019-12-31 | 阿尔米雷尔有限公司 | 包含反丁烯二酸二甲酯的药物组合物 |
| US11382889B2 (en) * | 2018-04-19 | 2022-07-12 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | NRF2 activators for the prevention and/or treatment of axonal degeneration |
| CN108904779B (zh) * | 2018-09-29 | 2019-12-03 | 南华大学 | 曲普瑞林的新应用 |
| CN109364058A (zh) * | 2018-12-05 | 2019-02-22 | 中南大学湘雅医院 | 富马酸酯及其可药用盐在制备治疗铁死亡相关疾病的药物中的应用 |
| PH12021552668A1 (en) | 2019-05-31 | 2022-09-19 | Curacle Co Ltd | Enteric tablet containing dimethyl fumarate |
| WO2021092536A1 (en) * | 2019-11-08 | 2021-05-14 | The Children's Hospital Of Philadelphia | Compositions and methods for treating macrophage activation syndrome |
| CN113117081B (zh) * | 2019-12-30 | 2024-12-24 | 上海海洋大学 | ZC3H12b基因或蛋白的用途及一种肝脏疾病动物模型的建立方法 |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| WO2022203432A1 (ko) | 2021-03-25 | 2022-09-29 | 주식회사 큐라클 | 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물 |
| CN115487297A (zh) * | 2021-06-17 | 2022-12-20 | 清华大学 | 治疗神经元蜡样质脂褐质沉积症的方法和药物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| AU2001271824A1 (en) * | 2000-07-05 | 2002-01-14 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| JP2004041208A (ja) * | 2002-07-15 | 2004-02-12 | Sankyo Co Ltd | インスリン抵抗性改善効果の評価方法 |
| SI1799196T1 (sl) | 2004-10-08 | 2016-10-28 | Forward Pharma A/S | Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline |
| EP1812374A1 (en) | 2004-11-10 | 2007-08-01 | Aditech Pharma AB | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| AU2006265113A1 (en) * | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| WO2007006308A1 (en) | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| US20080227847A1 (en) | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| WO2007042034A1 (en) | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| US20070224638A1 (en) * | 2006-03-27 | 2007-09-27 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| US20080089861A1 (en) * | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| EP2066335A4 (en) * | 2006-09-26 | 2010-01-20 | Univ Case Western Reserve | ZYTOKINSIGNALISIERUNG |
| EP2653873B8 (en) * | 2007-02-08 | 2022-08-24 | Biogen MA Inc. | Compositions and uses for treating Multiple Sclerosis |
| HUE032251T2 (en) * | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| EP2564839B1 (en) * | 2009-01-09 | 2016-05-11 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| EP3318249A1 (en) * | 2009-04-29 | 2018-05-09 | Biogen MA Inc. | Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis |
-
2010
- 2010-04-29 EP EP17202547.0A patent/EP3318249A1/en not_active Withdrawn
- 2010-04-29 JP JP2012508485A patent/JP2012525385A/ja not_active Withdrawn
- 2010-04-29 US US13/266,997 patent/US20120165404A1/en not_active Abandoned
- 2010-04-29 CN CN2010800215056A patent/CN102427727A/zh active Pending
- 2010-04-29 EP EP10770066A patent/EP2424357A4/en not_active Withdrawn
- 2010-04-29 AU AU2010242064A patent/AU2010242064A1/en not_active Abandoned
- 2010-04-29 NZ NZ595941A patent/NZ595941A/en not_active IP Right Cessation
- 2010-04-29 CN CN201410648177.2A patent/CN104523673A/zh active Pending
- 2010-04-29 EP EP18206136.6A patent/EP3466420A1/en not_active Withdrawn
- 2010-04-29 WO PCT/US2010/001282 patent/WO2010126605A1/en not_active Ceased
- 2010-04-29 CA CA2760133A patent/CA2760133A1/en not_active Abandoned
- 2010-04-29 NZ NZ617130A patent/NZ617130A/en not_active IP Right Cessation
-
2014
- 2014-11-13 US US14/540,136 patent/US20150132747A1/en not_active Abandoned
- 2014-11-27 JP JP2014239565A patent/JP2015044855A/ja active Pending
-
2016
- 2016-04-28 JP JP2016090250A patent/JP2016175926A/ja active Pending
-
2018
- 2018-11-07 HK HK18114182.9A patent/HK1255133A1/en unknown
- 2018-11-29 US US16/204,076 patent/US20190195860A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190195860A1 (en) | Treatment of Neurodegeneration and Neuroinflammation | |
| JP6941109B2 (ja) | Fxrアゴニストを使用するための方法 | |
| ES2797493T3 (es) | Formulaciones farmacéuticas de liberación controlada de nitazoxanida | |
| JP6038653B2 (ja) | 低頻度酢酸グラチラマー治療 | |
| US20140163100A1 (en) | Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content | |
| CN110693867A (zh) | 用于治疗代谢性病症的组合物和方法 | |
| CZ299960B6 (cs) | Použití derivátu kyseliny fumarové | |
| EA014189B1 (ru) | Применение флибансерина для лечения расстройств полового влечения в предклимактерический период | |
| JP2021152060A (ja) | アカンプロセートおよびd−サイクロセリンを使用する組み合わせ療法 | |
| CA2968980A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| CN110167595A (zh) | 非酒精性脂肪性肝病的预防及治疗药 | |
| TWI226238B (en) | Use of statins to inhibit formation of osteoclasts | |
| BRPI0418973A (pt) | composições de risedronato e seus métodos de uso | |
| US20200069716A1 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| JP2007523162A5 (cg-RX-API-DMAC7.html) | ||
| JP2003252795A (ja) | 軽度認知障害治療剤 | |
| MA27157A1 (fr) | Methode de traitement d'affections osseuses. | |
| CA3146794A1 (en) | Use of a benzoate containing composition to treat neurodegenerative disorders | |
| RU2000109303A (ru) | Производные пиперидинилметилоксазолидинона | |
| JPH07323043A (ja) | 爪の保護剤及び爪の保護剤キット | |
| Navarro et al. | P1-418 SUSTAINED DELIVERY OF SURFACE MODIFIED DONEPEZIL HCL LOADED PCL NANOPARTICLES FOR ALZHEIMER’S DISEASE | |
| JP2024541770A5 (cg-RX-API-DMAC7.html) | ||
| CA3213743A1 (en) | Methods of treating neurodegenerative disorders with intranasal nf-kappab essential modifier (nemo)-binding domain (nbd) peptide | |
| JP2005507884A5 (cg-RX-API-DMAC7.html) | ||
| HK40021394A (en) | Compositions and methods for treating metabolic disorders |